POSA56 A Cost-Effectiveness Analysis of Polatuzumab in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Portugal
Abstract
Authors
B Pinheiro M Cardoso M Borges A Launonen R Ho L Silva Miguel